Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | protein kinase, putative | 0.0415 | 0.2435 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0415 | 0.2435 | 0.5 |
Mycobacterium ulcerans | beta-ketoacyl synthase-like protein | 0.1343 | 1 | 0.5 |
Trypanosoma brucei | mitogen activated protein kinase 4, putative | 0.0415 | 0.2435 | 0.5 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0174 | 0.0479 | 0.5 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0174 | 0.0479 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0415 | 0.2435 | 0.5 |
Loa Loa (eye worm) | CMGC/MAPK/ERK1 protein kinase | 0.0415 | 0.2435 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0415 | 0.2435 | 0.5 |
Leishmania major | mitogen activated protein kinase, putative,map kinase, putative | 0.0415 | 0.2435 | 0.5 |
Mycobacterium tuberculosis | 3-oxoacyl-[acyl-carrier-protein] synthase III FabH (beta-ketoacyl-ACP synthase III) (KAS III) | 0.1343 | 1 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | 3-oxoacyl-ACP synthase | 0.1343 | 1 | 0.5 |
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.0415 | 0.2435 | 0.5 |
Onchocerca volvulus | Huntingtin homolog | 0.0119 | 0.0025 | 0.5 |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.1343 | 1 | 0.5 |
Echinococcus multilocularis | mitogen activated protein kinase 3 | 0.0415 | 0.2435 | 0.5 |
Mycobacterium ulcerans | 3-oxoacyl-ACP synthase | 0.1343 | 1 | 0.5 |
Plasmodium vivax | beta-ketoacyl-acyl carrier protein synthase III precursor, putative | 0.1343 | 1 | 0.5 |
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.0415 | 0.2435 | 0.5 |
Onchocerca volvulus | Huntingtin homolog | 0.0119 | 0.0025 | 0.5 |
Brugia malayi | MAP kinase sur-1 | 0.0415 | 0.2435 | 1 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0174 | 0.0479 | 0.5 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0174 | 0.0479 | 0.5 |
Giardia lamblia | Kinase, CMGC MAPK | 0.0415 | 0.2435 | 0.5 |
Echinococcus multilocularis | mitogen activated protein kinase | 0.0415 | 0.2435 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0119 | 0.0025 | 0.0101 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0415 | 0.2435 | 0.5 |
Plasmodium falciparum | beta-ketoacyl-ACP synthase III | 0.1343 | 1 | 0.5 |
Trypanosoma cruzi | mitogen activated protein kinase 4, putative | 0.0415 | 0.2435 | 0.5 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0415 | 0.2435 | 0.5 |
Brugia malayi | hypothetical protein | 0.0119 | 0.0025 | 0.0101 |
Entamoeba histolytica | fatty acid elongase, putative | 0.0174 | 0.0479 | 0.5 |
Trypanosoma cruzi | mitogen activated protein kinase 2, putative | 0.0415 | 0.2435 | 0.5 |
Leishmania major | mitogen activated protein kinase 4, putative;with=GeneDB:LmxM19.1440 | 0.0415 | 0.2435 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0119 | 0.0025 | 0.0101 |
Echinococcus granulosus | mitogen activated protein kinase | 0.0415 | 0.2435 | 0.5 |
Echinococcus granulosus | mitogen activated protein kinase 3 | 0.0415 | 0.2435 | 0.5 |
Toxoplasma gondii | CMGC kinase, MAPK family (ERK) MAPK-1 | 0.0415 | 0.2435 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | > 10 uM | Concentration of the compound inhibiting Candida beta-1,3-glucan synthesis was determined in a Candida albicans cell culture | ChEMBL. | 1495015 |
MFC (functional) | > 64 ug ml-1 | Antifungal activity of the compound on Candida albicans MY1055. | ChEMBL. | 1495015 |
MFC (functional) | > 64 ug ml-1 | Antifungal activity of the compound on Candida albicans MY1208. | ChEMBL. | 1495015 |
MFC (functional) | > 64 ug ml-1 | Antifungal activity of the compound on Candida albicans MY1028. | ChEMBL. | 1495015 |
MFC (functional) | > 64 ug ml-1 | Antifungal activity of the compound on Candida tropicalis MY101 | ChEMBL. | 1495015 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.